Denali Therapeutics Inc. 8-K Filing
Ticker: DNLI · Form: 8-K · Filed: Mar 31, 2026 · CIK: 0001714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $200.0 million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Denali Therapeutics Inc. (ticker: DNLI) to the SEC on Mar 31, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ich registered Common Stock, par value $0.01 per share DNLI Nasdaq Global Select Mar); $200.0 million (On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with th).
How long is this filing?
Denali Therapeutics Inc.'s 8-K filing is 2 pages with approximately 485 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2026-03-31 08:30:09
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share DNLI Nasdaq Global Select Mar
- $200.0 million — On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with th
Filing Documents
- dnli-20260327.htm (8-K) — 28KB
- 0001714899-26-000036.txt ( ) — 139KB
- dnli-20260327.xsd (EX-101.SCH) — 2KB
- dnli-20260327_lab.xml (EX-101.LAB) — 21KB
- dnli-20260327_pre.xml (EX-101.PRE) — 12KB
- dnli-20260327_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Royalty Agreement Closing and Funding On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with the closing of the transactions under the Royalty Agreement. The closing followed the U.S. Food and Drug and Administration's accelerated approval of tividenofusp alfa on March 24, 2026. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: March 31, 2026 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer